Bo Chen

Bo Chen has an extensive work history in the field of medical research and development. They started their career as a Research Assistant at The University of Texas System in 2004, where they focused on developing an infrared imaging system and conducting in vivo animal studies. In 2007, Chen joined Cynosure, Inc. as a Research Scientist and worked their way up to Principal Scientist and Executive Staff. During their time at Cynosure, they played a key role in achieving double-digit revenue growth and played a pivotal role in the successful acquisition of the company by Hologic for $1.65B. In 2018, Chen joined miraDry, Inc. as Vice President of R&D before eventually returning to Cynosure, LLC. in 2020. At Cynosure, LLC., they held the positions of Vice President of Translational Science, Research Development Consultant, and currently Vice President of Translational Science and Clinical Development.

Bo Chen received a Bachelor's and Master's degree in physics from Tsinghua University, where they studied from 1996 to 2003. Afterward, they pursued their PhD in Biomedical Engineering at The University of Texas at Austin, completing their studies from 2003 to 2007.